Pagibaximab (formerly BSYX-A110)

DRUG2 trials

Sponsors

Biosynexus Incorporated

Conditions

Neonatal Staphylococcal SepsisStaphylococcal Sepsis

Phase 1

Safety and Pharmacokinetics Study in VLBW Neonates With BSYX-A110

CompletedNCT00631878

Biosynexus IncorporatedNeonatal Staphylococcal Sepsis

Start: 2001-11-30End: 2003-08-31Updated: 2008-03-10

Phase 2

Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity Study in VLBW Neonates of BSYX-A110

CompletedNCT00631800

Biosynexus IncorporatedStaphylococcal Sepsis

Start: 2003-05-31End: 2004-11-30Updated: 2008-03-10